avutometinib and sotorasib

Phase 2Small molecule

VVerastem, Inc.

avutometinib and sotorasib is one of 52 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerActive, not recruiting

AvutometinibActive, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

AvutometinibPhase 2

Active, not recruiting

Competition

Competitive Landscape

207 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

33 2

Hycamtin

MMeitheal

Phase 3

26 3

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

24 5

Imfinzi

AstraZeneca

Phase 3

8 6

Opdivo

Bristol-Myers Squibb

Phase 3

8 7

Adriamycin

Pfizer

Phase 3

8 8

Afinitor

Novartis

Phase 3

2 9

Neulasta

Amgen

Phase 3

2 10

Taxotere

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Ovarian Cancer

NCT04625270

Q2 2027

Phase 1/2Active, not recruiting

Avutometinib

NCT05074810

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Completed·VVerastem, Inc.·Phase 2·NCT04620330·90 enrolled

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)

Completed·VVerastem, Inc.·Preclinical·NCT05375994·12 enrolled

Ovarian Cancer1 trial

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Active, not recruiting·VVerastem, Inc.·Phase 2·NCT04625270·225 enrolled

Avutometinib1 trial

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Active, not recruiting·VVerastem, Inc.·Phase 1/2·NCT05074810·153 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for avutometinib and sotorasib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — avutometinib and sotorasib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for avutometinib and sotorasib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Verastem, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVerastem, Inc.

avutometinib and sotorasib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Ovarian Cancer1 trial

Avutometinib1 trial

References

Drug Info

Quick Facts

Related News